JPRN-UMIN000001749已完成1 期
Phase I study of CMV specific CTL for treatment of refractory CMV infection after allogeneic hematopoietic stem cell transplantation - Phase I study of CMV specific CTL for treatment of refractory CMV infection after allogeneic hematopoietic stem cell transplantation
Department of Pediatrics, Nagoya University Graduate School of Medicine0 个研究点目标入组 5 人开始时间: 2009年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe or uncontrollable bacterial, fungal, and viral (except CMV) infection 2. Uncontrollable acute and chronic GVHD 3. Psychoses 4. History of allergic reaction to albumin
研究者
相似试验
已完成
1 期
Phase I study of CMV specific CTL generated from third party for treatment of antiviral drug-resistant CMV infection after allogeneic stem cell transplantatioJPRN-UMIN000015556agoya University Graduate School of Medicine, Department of Hematology and Oncology9
进行中（未招募）
1 期
CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.EUCTR2013-004953-26-BEGhent University Hospital20
已完成
2 期
Phase II study of pre-emptive therapy against CMV-associated disesase by valganciclovir after allogeneic hematopoietic stem cell transplantatioPatients with CMV reactivation after allogeneic hematopoietic stem cell transplantationJPRN-UMIN000000953Dept of 1st Intern Med, Kyushu Univ Hospital10
已完成
1 期
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell TransplantsCytomegalovirus InfectionsNCT00673868Milton S. Hershey Medical Center2
已完成
1 期
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18